The advanced BRAF-mutant melanoma adaptive trial (NCT03543969) administers Encorafenib (a small molecule BRAF-inhibitor) and Binimetinib (a selective MEK inhibitor) in combination adaptively, with Nivolumab (an immune checkpoint inhibitor that blocks PD-1) administered continuously. Here, BRAF is linked to melanoma.